It was found in breast cancer cells that are resistant to palbociclib which the transcriptions of AP-1 and C-FOS were increased, and AP-1 blockade in combination with palbociclib could effectively inhibit cell proliferation and reduce pRb and CDK2 levels as compared to single agent treatment (77). This evidence concerns the gene RB1 and breast carcinoma.